Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891344525> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2891344525 abstract "7524 Background: Ibrutinib (ibr), a first-in-class, once-daily inhibitor of Bruton’s tyrosine kinase, is indicated by FDA for treatment (Tx) of patients (pts) with CLL. Following the outcome of the RESONATE-2 trial, ibr was approved as the first chemotherapy-free Tx option for treatment-naïve (TN) pts. In this study, ibr reduced the risk of progression or death by 84% compared with chlorambucil (chl). To assess the impact of ibrutinib vs this traditional chemotherapeutic agent on the immune system, quantitative changes in circulating cells were studied throughout the first year of Tx. Methods: Immunophenotypic analyses were performed by flow cytometry on peripheral blood to assess lymphoid and myeloid cells of TN CLL pts who received 420 mg ibr once daily (n=50) or 0.5-0.8 mg/kg chl twice a month (n=30). Medians of statistically significant changes (p<0.05, Wilcoxon test) in absolute counts of 1-year paired samples (pre-dose vs 1-year) are reported. Results: Chl progressively reduced circulating B, T, NK, NKT cells, myeloid derived suppressor cells (MDSC), and monocytes by 69%-99%. All development stages of CD4 + and CD8 + T cells, except stem cell memory T cells (T SCM ), decreased by 51%-90%. Regulatory T cells (Treg) and PD1 + T cells also decreased similarly; however, long-term activated T cells (T LA ) were not impacted. On the other hand, ibr mainly reduced B cells (90%), MDSC (61%) and some T cells, specifically T LA , PD1 + T cells, Treg and effector T cells (27-52%). Naïve T cells, T SCM , central memory T cells and NK cells were spared throughout the full year of Tx. Classical monocytes were increased (+187%), while non-classical monocytes and intermediate monocytes remained relatively steady. Conclusions: Chl, a traditional chemotherapy, affected non-specifically most immune cell subsets in circulation, although surprisingly it did not affect T LA which have been reported as dysfunctional in CLL. Ibr represents a more targeted Tx approach than cytotoxic chemotherapy; essentially B cells, abnormal T subsets (T LA , PD1 + T, Treg) and pro-tumor MDSCs were reduced. However, ibr preserved naïve T cells, NK cells and monocytes, which are important for mounting anti-tumor responses. Clinical trial information: NCT01722487." @default.
- W2891344525 created "2018-09-27" @default.
- W2891344525 creator A5001483654 @default.
- W2891344525 creator A5025586566 @default.
- W2891344525 creator A5036828560 @default.
- W2891344525 creator A5040222712 @default.
- W2891344525 creator A5056327118 @default.
- W2891344525 creator A5058755419 @default.
- W2891344525 creator A5062041233 @default.
- W2891344525 creator A5062625211 @default.
- W2891344525 creator A5062975737 @default.
- W2891344525 creator A5081161234 @default.
- W2891344525 date "2017-05-20" @default.
- W2891344525 modified "2023-09-27" @default.
- W2891344525 title "Ibrutinib vs chlorambucil: Immunophenotypic and quantitative impacts on circulating immune cells in chronic lymphocytic leukemia (CLL)." @default.
- W2891344525 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.7524" @default.
- W2891344525 hasPublicationYear "2017" @default.
- W2891344525 type Work @default.
- W2891344525 sameAs 2891344525 @default.
- W2891344525 citedByCount "0" @default.
- W2891344525 crossrefType "journal-article" @default.
- W2891344525 hasAuthorship W2891344525A5001483654 @default.
- W2891344525 hasAuthorship W2891344525A5025586566 @default.
- W2891344525 hasAuthorship W2891344525A5036828560 @default.
- W2891344525 hasAuthorship W2891344525A5040222712 @default.
- W2891344525 hasAuthorship W2891344525A5056327118 @default.
- W2891344525 hasAuthorship W2891344525A5058755419 @default.
- W2891344525 hasAuthorship W2891344525A5062041233 @default.
- W2891344525 hasAuthorship W2891344525A5062625211 @default.
- W2891344525 hasAuthorship W2891344525A5062975737 @default.
- W2891344525 hasAuthorship W2891344525A5081161234 @default.
- W2891344525 hasConcept C126322002 @default.
- W2891344525 hasConcept C143998085 @default.
- W2891344525 hasConcept C203014093 @default.
- W2891344525 hasConcept C2776694085 @default.
- W2891344525 hasConcept C2776755627 @default.
- W2891344525 hasConcept C2777866208 @default.
- W2891344525 hasConcept C2777938653 @default.
- W2891344525 hasConcept C2778461978 @default.
- W2891344525 hasConcept C2779878957 @default.
- W2891344525 hasConcept C502942594 @default.
- W2891344525 hasConcept C71924100 @default.
- W2891344525 hasConcept C8891405 @default.
- W2891344525 hasConceptScore W2891344525C126322002 @default.
- W2891344525 hasConceptScore W2891344525C143998085 @default.
- W2891344525 hasConceptScore W2891344525C203014093 @default.
- W2891344525 hasConceptScore W2891344525C2776694085 @default.
- W2891344525 hasConceptScore W2891344525C2776755627 @default.
- W2891344525 hasConceptScore W2891344525C2777866208 @default.
- W2891344525 hasConceptScore W2891344525C2777938653 @default.
- W2891344525 hasConceptScore W2891344525C2778461978 @default.
- W2891344525 hasConceptScore W2891344525C2779878957 @default.
- W2891344525 hasConceptScore W2891344525C502942594 @default.
- W2891344525 hasConceptScore W2891344525C71924100 @default.
- W2891344525 hasConceptScore W2891344525C8891405 @default.
- W2891344525 hasLocation W28913445251 @default.
- W2891344525 hasOpenAccess W2891344525 @default.
- W2891344525 hasPrimaryLocation W28913445251 @default.
- W2891344525 hasRelatedWork W1984436001 @default.
- W2891344525 hasRelatedWork W2022025463 @default.
- W2891344525 hasRelatedWork W2095408122 @default.
- W2891344525 hasRelatedWork W2233829104 @default.
- W2891344525 hasRelatedWork W2335814416 @default.
- W2891344525 hasRelatedWork W2527403886 @default.
- W2891344525 hasRelatedWork W2533718237 @default.
- W2891344525 hasRelatedWork W2596105889 @default.
- W2891344525 hasRelatedWork W2767685521 @default.
- W2891344525 hasRelatedWork W2804984547 @default.
- W2891344525 hasRelatedWork W2890402465 @default.
- W2891344525 hasRelatedWork W2910970388 @default.
- W2891344525 hasRelatedWork W2920968324 @default.
- W2891344525 hasRelatedWork W2935896439 @default.
- W2891344525 hasRelatedWork W2943425539 @default.
- W2891344525 hasRelatedWork W2943776711 @default.
- W2891344525 hasRelatedWork W2943843203 @default.
- W2891344525 hasRelatedWork W3032320418 @default.
- W2891344525 hasRelatedWork W3043694179 @default.
- W2891344525 hasRelatedWork W3043703607 @default.
- W2891344525 isParatext "false" @default.
- W2891344525 isRetracted "false" @default.
- W2891344525 magId "2891344525" @default.
- W2891344525 workType "article" @default.